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Summary
 Background To evaluate the impact of tumour surface area (TSA) on survival of patients treat-
ed with 192Ir implantation for glioblastoma multiforme (GBM).
 Methods/Materials The analysis of survival and prognostic factors was performed based on a retro-
spective study group of 120 patients (74 males and 46 females; mean age 53 years; 
mean KPS score 74.6) irradiated with 192Ir for GBM between 1999 and 2003. There 
were 72 (60%) patients with recurrent and 48 (40%) with primary inoperable tu-
mour. Patients with recurrences were initially treated with surgery and external 
beam radiotherapy (EBRT; mean total dose (MTD) 53.5Gy). Individuals with pri-
mary inoperable glioblastoma underwent EBRT (MTD 37.2Gy) after brachyther-
apy completion. All patients were irradiated with 192Ir with a total dose of 15Gy 
given in 5 fractions.
 Results For the total group of patients 1-year and 2-year survival were 22% and 11%, re-
spectively, with a median survival time (MST) of 6.1 months. The multivariate 
Cox analysis of the best ﬁ t (Chi²=22.98, p=0.000041) distinguished such varia-
bles as: patient age (p=0.002), performance status (p=0.04) and tumour surface 
area (p=0.04) to signiﬁ cantly affect survival. Patients with TSA<90 cm2 had bet-
ter prognosis compared to those with TSA≥90cm2 (p<0.001).
 Conclusions Tumour surface area is an independent prognostic factor in patients irradiated 
with 192Ir for glioblastoma multiforme. TSA less than 90cm2 predicts signiﬁ cant-
ly longer survival and appears to be a more powerful prognostic variable than tu-
mour volume.
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BACKGROUND
Despite aggressive standard treatment (surgery 
followed by external beam irradiation and chem-
otherapy in speciﬁ ed cases) glioblastoma multi-
forme (GBM) tumours have remained incurable 
and highly lethal. Interstitial brachytherapy is an 
established treatment option in selected patients 
with recurrent [1–3] and primary [4–6] malig-
nant gliomas, enabling the deposition of a high 
radiation dose within the target volume, while 
sparing surrounding normal tissues. Local recur-
rence after implantation in a characteristic form 
of tumour regrowth within or at the margin of 
an irradiated ﬁ eld is the most common cause of 
treatment failure [7,8].
Searching for clinical and histological variables af-
fecting survival in patients with malignant glioma is 
virtually a procedure leading to the optimal choice 
of therapeutic strategy and thus an improvement 
of treatment results. The prognostic criteria pub-
lished by the Radiation Therapy Oncology Group 
(RTOG) in its recursive partitioning analysis (RPA) 
of randomized malignant glioma trials [9] are cur-
rently obligatory and indicate such variables as low-
er histological grade, greater extent of surgical re-
section, younger age, high Karnofsky Performance 
Status (KPS) score and favourable neurological 
state to predict better survival outcomes. More re-
cently, tumour volume has been reported to be a 
signiﬁ cant prognostic factor in patients with both 
primary [10] and recurrent [11] glioma treated 
with brachytherapy techniques. However, the prog-
nostic effect of tumour volume has been proven 
to disappear when patients are stratiﬁ ed using the 
RTOG’s RPA criteria [10].
As suggested by inhomogeneous contrast en-
hancement on MRI images of GBM [12], a dy-
namic increase in its volume ﬁ nds expression in 
a marginal expansion and a cumulative contri-
bution of necrosis, haemorrhage foci as well as 
vascular and cystic areas in the central part of 
the tumour. Therefore, we hypothesized that a 
parameter that could better describe the popu-
lation of viable proliferating malignant glioma 
cells, and consistently responsible for clinical ef-
fects, is not the total volume of the tumour but 
rather its surface area, which reﬂ ects the most 
external, actively growing portion of the neo-
plasm. Thus, the aim of this study was to eval-
uate the impact of the tumour surface area on 
survival of patients with both primarily inoper-
able and recurrent glioblastoma irradiated with 
192Ir implantation.
METHODS AND MATERIALS
Patient data
Between July 1999 and December 2003, 219 pa-
tients were treated with 192Ir implantation for re-
current or primary malignant brain tumour at the 
Chair and Clinic of Oncology and Brachytherapy. 
In this group, the stereotactic biopsy results con-
ﬁ rmed glioblastoma multiforme in 120 cases. 
Other tumours were histologically classiﬁ ed as: 
anaplastic astrocytoma (43 patients), metastasis 
(25 pts.), anaplastic oligoastrocytoma (14 pts.), 
anaplastic oligodendroglioma (10 pts.), anaplas-
tic ependymoma (6 pts.) and gliosarcoma (1 pt.). 
The study group consisted of 120 patients with the 
diagnosis of glioblastoma multiforme: 48 (40%) 
had primarily inoperable tumour and were re-
ferred for EBRT after completion of brachyther-
apy; 72 (60%) had recurrent tumour and were 
previously treated with a combination of sur-
gery and external beam radiotherapy (EBRT). 
The mean time to relapse was 68.7 weeks, range 
4.7–232. In all patients conformal EBRT tech-
niques and megavoltage linear accelerators were 
used. The EBRT total doses for primarily inopera-
ble tumours ranged between 20 and 54Gy (mean 
37.2±11.2) given in 1.8–4.0Gy-size fractions to the 
tumour volume with a 3cm margin. The EBRT 
total doses for initially resected GBMs ranged 
between 20 and 60Gy (mean 53.2Gy±12.3) giv-
en in 1.8–4.0Gy-size fractions to the primary tu-
mour volume with the same margin.
Patients were selected for brachytherapy accord-
ing to the following criteria: pathologic conﬁ rma-
tion of GBM, KPS≥50, unifocal (except for 2 pa-
tients) supratentorial disease of a maximum size 
≤6cm, with no involvement of the corpus callo-
sum, informed patient consent to implantation. 
The applicability of the method was assessed in 
each case by the radiation oncologist together 
with the neurosurgeon.
The clinical patient characteristics are given in 
Table 1. Seventy-four males (62%) and 46 females 
(38%) were implanted. The mean age of patients 
was 53.2±11.6 years (range 28–76). The mean KPS 
score was 74.6±14.1 (range 50–100).
Implantation and irradiation procedure
A day prior to implantation all patients underwent 
magnetic resonance imaging (MRI) with contrast 
medium (1.5 T scanner, Siemens). T1-weight-
ed images (3mm-spaced) were substantially 
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transferred to the computer treatment plan-
ning system (BrainLAB, AG, Germany), in which 
tumour volume and the objects required for the 
fusion of MRI with CT scans (the eyeballs and 
pineal gland) were outlined by the radiation 
oncologist. On the day of implantation comput-
ed tomography (CT) was carried out using the 
stereotactic frame (BrainLAB, AG, Germany) af-
ﬁ xed to the skull under local anaesthesia. CT im-
ages (5mm-spaced) were also transferred to the 
BrainLAB system and, after delineation of the 
fusion objects, they were automatically superim-
posed onto corresponding MRI scans. After im-
age fusion the radiation oncologist together with 
the neurosurgeon planned the biopsy trajectory 
and radiation dose distribution. Stereotactic im-
plantation was executed in the operating room 
under sedoanalgesia and preceded by tumour bi-
opsy. A plastic tube (a canal for an internal cath-
eter) was introduced through the skull twist drill 
hole to the determined depth and the tube’s ends 
sutured to the scalp. The wound was protected 
with a chamber dressing fulﬁ lled with crystalline 
penicillin, and corticosteroids as well as prophy-
lactic antibiotics (3rd generation cephalosporin) 
were administered to patients until brachythera-
py completion. The treatment started 1–2 days af-
ter implantation. Patients were irradiated in the 
brachytherapy room using the MicroSelectron 
HDR (GENIE, Nucletron, The Netherlands). 
The 192Ir stepping source was afterloaded into 
the internal catheter inserted directly before 
treatment into the implanted plastic tube and 
taken out after each fraction. Once brachyther-
apy had been completed, plastic tubes were re-
moved by the radiation oncologist and the scalp 
wound was sutured.
The prescribed total radiation dose was 15Gy giv-
en in 5 fractions (1 fraction per day) to the vol-
ume of enhancing recurrent tumour or to the vol-
ume of enhancing primary tumour with a margin 
of 5mm. The radiation dose distribution parame-
ters are given in Table 2. In each case we endeav-
oured to achieve conformity index (CI; the ra-
tio of treated volume to target volume) <2.5 and 
coverage factor (CF; the proportion of the target 
volume covered by the reference isodose) >95%. 
In order to improve the dose distribution 33 pa-
tients (27%) were implanted with two catheters. 
Additionally, the minimal dose (Dmin) within the 
target volume was determined, but it did not in-
ﬂ uence dose distribution planning.
Tumour volume and tumour surface area 
determination
Tumour volumes (TV) were calculated automati-
cally by the BrainLAB software based on enhanc-
ing lesions manually delineated on MRI scans.
In order to determine tumour surface areas 
(TSA) the MRI slices with outlined target vol-
umes were exported into the 3DDoctor software 
(Able Software Corp, USA) in the BMP format. 
Subsequently the bitmap series was transformed 
into the DICOM format and pixel sizes as well as 
interslice distances were edited. Finally the soft-
ware algorithms of the formation of spatial tu-
mour images (using the function of automatic 
segmentation and rendering) enabled the calcu-
lation of TV and TSA with a triangulation meth-
od (Figure 1).
Additionally, we introduced a parameter called 
“sphericity index” (SI) to describe the irregu-
larity of the tumour shape and also assess its im-
pact on survival. We deﬁ ned SI as a quotient of 
two surface areas: of the tumour, and of a sphere 
having the same volume.
Statistical methods
The correctness of TSA calculations was estimat-
ed by determining the correlation between TVs 
Variable Value
Age [years]
 Mean 53.2±11.6
 Range 28–76
KPS
 Mean 74.6±14.1
 Range 50–100
Sex
 Male  74 (62.0%)
 Female  46 (38.0%)
Tumour
 Primarily inoperable  48 (40.0%)
 Recurrent  72 (60.0%)
 < 30cm3  38 (32.5%)*
 ≥ 30cm3  79 (67.5%)*
 < 90 cm2  59 (50.4%)*
 ≥90cm2  58 (49.6%)*
Table 1. Patient characteristics (n=120).
n=117.
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calculated with the 3DDoctor software and those 
obtained from the BrainLAB system using linear 
regression analysis.
The Kaplan-Meier method was employed to as-
sess survival rates from the day of implantation 
to the time of patient death or the date of the 
analysis. Survival data of the speciﬁ ed subgroups 
of patients were compared using the log-rank 
test. In order to evaluate variables affecting sur-
vival, univariate and multivariate analyses were 
performed using the Cox proportional hazards 
model. The ﬁ tting of multivariate analyses was 
estimated with the Chi2 test.
All statistical analyses were performed using 
the software Statistica 7.1 (StatSoft Inc., Tulsa, 
USA).
RESULTS
We analysed 117 cases (97.5%) out of the 120 
that entered the study due to the impossibility 
of retrieving radiological data of 3 patients. The 
mean follow-up time was 8.9 months (range 0.3–
70.8). There were 4 censored and 113 complete 
observations.
The mean TV computed with the 3DDoctor soft-
ware was 50.6cm3±34.2 (range 1.5–153), corre-
sponding to a sphere diameter of approximately 
4.3cm±1.13 (range 1.5–6.8). The mean TSA was 
94.5cm2±51.4 (range 4.3–247). There was a high 
correlation between TVs calculated with the 
3DDoctor software and those obtained from the 
BrainLAB system (R=0.99; p<0.001; Figure 2). 
Thus, we assumed that TSA assignment was not 
burdened with a meaningful error. Tumour vol-
umes were stratiﬁ ed as <30cm3 and ≥30cm3. There 
were 38 (32.5%) analysed patients with TV <30 
cm3 and 79 (67.5%) with TV ≥30cm3. Tumour sur-
face areas were stratiﬁ ed as <90 cm2 and ≥90cm2. 
There were 59 (50.4%) patients with TSA <90cm2 
and 58 (49.6%) with TSA ≥90cm2. The calculated 
tumour parameters are given in Table 3.
For the total group of 120 patients 1-year and 
2-year survival were 22% and 11%, respectively, 
with a median survival time (MST) of 6.1 months 
(range 0.26–70.8; Figure 3). For the subgroup of 
patients suffering from recurrent GBM 1-year sur-
vival was 26%, 2-year survival 13%, and MST 6.9 
months (range 0.36-70.8). For the subgroup of 
primary GBMs they were, respectively, 17%, 7%, 
and 4 months (range 0.26–30.1). There was a sta-
tistically signiﬁ cant difference in survival between 
the subgroups (p=0.0038; Figure 4).
Since individuals with recurrent tumours 
had longer survival than those with primarily 
Mean Minimum Maximum Standard deviation
Conformity Index [%] 2.3 1.3 7.6 0.8
Coverage Factor 96.7 83.0 100.0 3.2
Dmin [Gy] 11.0 5.0 19.0 3.1
Table 2. Dose distribution parameters.
Figure 1. 3DDoctor software – delineated MRI image of a tumour 
(A), spatial image (B) and results of TV and TSA calculations (C).
C
B
A
Figure 2. Relationship between tumour volumes calculated with 
the 3DDoctor software and tumour volumes obtained from the 
BrainLAB system.
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inoperable GBMs we decided to analyse both 
subgroups together. Only after combining them 
did a statistical signiﬁ cance of prognostic fac-
tors, other than age and KPS score, appear. As 
shown in Table 4, in the univariate Cox mod-
el there were four variables which we identi-
ﬁ ed to signiﬁ cantly affect survival: patient age 
(p=0.001), performance status (p=0.003), tu-
mour volume (p=0.001) and tumour surface 
area (p = 0.002). No radiation dose distribution 
parameters (CI, CF, Dmin) appeared to predict 
survival. The two multivariate Cox analyses per-
formed displayed different ﬁ t determined by 
the Chi2 test. The analysis of better adjustment 
(Chi²=22.98; p=0.000041) distinguished such var-
iables as: patient age (p=0.002), performance sta-
tus (p=0.04) and tumour surface area (p=0.04; 
Table 5) to be signiﬁ cant and independent pre-
dictors of survival. Patients with TSA <90cm2 
had signiﬁ cantly better prognosis compared to 
those with TSA ≥90cm2 (p =0.00038). One-year 
and 2-year survival and MST for the former sub-
group were 38%, 19% and 8.5 months, where-
as the corresponding values for the latter sub-
group were 10%, 2% and 4.5 months (Figure 5). 
In the multivariate Cox analysis of worse ﬁ tting 
(Chi²=22.78; p=0.000045) patient age, KPS score 
Mean Minimum Maximum Standard deviation
Tumour volume [cm3] 50.6 1.5 153.8 34.2
Tumour surface area [cm2] 94.5 4.3 247.0 51.4
Sphericity index 1.5 1.24 2.6 0.26
Table 3. Tumour parameters.
Beta coeffi  cient Standard error Hazard ratio p
Age 0.03 0.01 1.03 0.001
KPS –0.03 0.01 0.97 0.003
Tumour volume [cm3] 0.03 0.01 1.03 0.001
Tumour surface area [cm2] 0.01 0.002 1.01 0.002
Coverage Factor –0.05 0.14 0.95 0.69
Conformity Index [%] 0.03 0.16 1.03 0.85
Dmin [Gy] 0.003 0.001 1.00 0.09
Sphericity index 0.44 0.38 1.5 0.2
Table 4. Univariate analysis of prognostic variables – Cox proportional hazards model.
Figure 3. Survival of the total group of patients (n=120).
Beta coeffi  cient Standard error Hazard ratio p
Age 0.03 0.01 1.03 0.002
KPS –0.02 0.01 0.98 0.04
Tumour surface area 0.004 0.0001 1.004 0.04
Table 5. Multivariate analysis of prognostic variables – Cox proportional hazards model (Chi2=22.98; p=0.000041).
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and tumour volume appeared to signiﬁ cantly af-
fect survival (p=0.001, 0.047 and 0.042, respective-
ly; Table 6). Patients with smaller TVs (<30cm3) 
displayed signiﬁ cantly better survival outcomes 
(p=0.0003; 1-year and 2-year survival and MST 
were 48%, 25% and 11.4 months, respectively) 
compared to those with TVs ≥30cm3 (17%, 5% 
and 5.3 months, respectively; Figure 6).
DISCUSSION
The complex biological characteristics of GBM, 
including high proliferation rate [13], striking 
motility [14], great contribution of hypoxic cells 
[15] and rapid neoangiogenesis [16], is common-
ly considered to be responsible for the invariably 
poor prognosis of affected patients. Determining 
variables that would relate to natural GBM fea-
tures as well as being clinically available seems to 
be a key to the choice of optimal patient man-
agement. The tumour surface area reﬂ ects the 
marginal tumour expansion and can be relative-
ly easily obtained from MRI data. Since the radi-
ographic image of GBM suggests that its central 
portion is mainly occupied by necrotic, vascular, 
haemorrhage and cystic areas, we assumed that 
the most external tumour layer, which TSA math-
ematically describes, might determine treatment 
failure. In fact, we demonstrate in our study that 
TSA is an independent prognostic factor in im-
planted GBM patients. In this highly selected and 
uniformly treated group TSA less than 90cm2 
predicts signiﬁ cantly better prognosis than TSA 
≥90cm2. Indeed, the statistical analysis also con-
ﬁ rmed the recent reports on the prognostic value 
of GBM volume [10,11]; however, the Chi² test in-
dicated TSA as a parameter that better describes 
Beta coeffi  cient Standard error Hazard ratio p
Age 0.03 0.01 1.03 0.001
KPS –0.02 0.01 0.98 0.05
Tumour volume 0.01 0.003 1.001 0.04
Table 6. Multivariate analysis of prognostic variables – Cox proportional hazards model (Chi2=22.78; p=0.000045).
Figure 4. Survival of patients according to tumour characteristic. 
Solid line – patients with recurrent tumours; dashed line – patients 
with primarily inoperable tumours. Log-rank test was signifi cant 
(p=0.0038).
Figure 5. Survival of patients according to tumour surface area. 
Solid line – patients with TSA <90cm2; dashed line – patients with 
TSA ≥90cm2. Log-rank test was signifi cant (p=0.0038).
Figure 6. Survival of patients according to tumour volume. Solid 
line – patients with TV <30cm3; dashed line – patients with TV 
≥30cm3. Log-rank test was signifi cant (p=0.0003).
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survival outcomes of patients treated with brachy-
therapy techniques. Our ﬁ ndings seem to be con-
sistent with the conclusions of the RTOG recur-
sive analysis. Its results did not identify tumour 
size itself as a factor of prognostic value [9], but, 
similarly to other studies [17–19], distinguished 
the extent of GBM surgical resection as one of 
the survival predictors. One can assume that the 
unfavourable effect of insufﬁ cient cytoreduction 
on survival results from the presence of residual 
disease mainly on the periphery of the originally 
detected tumour. In this context both the com-
pleteness of neoplasm tissue removal and TSA 
describe the impact of marginal tumour zone 
on treatment efﬁ ciency.
In our opinion TSA appeared to be a prognos-
tic variable since it relates not only to a periph-
eral purely cellular active layer of neoplasm but 
it also reﬂ ects, which may be even more impor-
tant, a characteristic GBM feature of massive mi-
croscopic invasion. As several histological analyses 
have shown, malignant gliomas cannot be consid-
ered as strictly solid tumours since they display 
an enormous capacity for intracerebral dissemi-
nation [20–22]. Experimental studies have dem-
onstrated that the size of the area of microscopic 
tumour cell invasion remains relatively stable and 
is approximately 2.5 times greater than the area 
outlined by the solid tumour mass [23]. TSA may 
give us then indirect information, which we can-
not obtain from radiographic data (CT/MRI), of 
the extent of GBM spread and thus may be help-
ful in predicting patient prognosis. Spectacular 
examples of this dependence were in our study 
two cases of multifocal disease. Although this is 
a condition commonly considered to be a con-
traindication to brachytherapy, we decided to im-
plant two young patients with bifocal GBM and a 
high KPS score. The volumes of single foci were 
small but their total TASs were high, which found 
a reﬂ ection in the short survival times of both pa-
tients (1.1 and 5.6 months).
It is a little surprising that the study results did 
not conﬁ rm the impact of the tumour shape (ex-
pressed as the sphericity index) on survival, espe-
cially as the irregular pattern of inﬁ ltration has 
been stressed to be one of GBM’s features unfa-
vourably affecting patient prognosis. However, if 
we assume that the extent of the spread of neo-
plasm cells depends on TSA, the shape of a given 
tumour area seems to have minor importance.
Since the commonly used imaging modalities 
(CT/MRI) do not allow one to assess precisely 
the boundaries of malignant glioma, TSA may be 
considered as a kind of indicator of the intrac-
erebral extent of a tumour and thus a predictor 
of survival in patients treated with brachytherapy 
for primary and recurrent glioblastoma. To our 
best knowledge this is the ﬁ rst study demonstrat-
ing signiﬁ cantly better prognosis for a GBM sur-
face area less than 90cm2.
CONCLUSIONS
Tumour surface area is an independent prognos-
tic factor in patients with primary and recurrent 
glioblastoma irradiated with 192Ir implantation. 
TSA <90cm2 predicts signiﬁ cantly better survival, 
with a median survival time of 8.5 months. TSA 
appears to be a more powerful prognostic varia-
ble than tumour volume.
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